PetMed Express, Inc. (NASDAQ:PETS) – Equities research analysts at Northcoast Research increased their Q3 2018 earnings per share estimates for PetMed Express in a research note issued to investors on Tuesday. Northcoast Research analyst E. Snyder now forecasts that the company will earn $0.32 per share for the quarter, up from their prior estimate of $0.30. Northcoast Research currently has a “Buy” rating and a $54.00 target price on the stock. Northcoast Research also issued estimates for PetMed Express’ FY2018 earnings at $1.60 EPS, Q1 2019 earnings at $0.49 EPS, Q2 2019 earnings at $0.42 EPS, Q3 2019 earnings at $0.34 EPS, Q4 2019 earnings at $0.41 EPS and FY2019 earnings at $1.66 EPS.
PetMed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $63.41 million. During the same quarter in the previous year, the firm posted $0.24 EPS. The business’s revenue was up 9.7% compared to the same quarter last year.
Other research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of PetMed Express from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a research report on Thursday, August 24th. BidaskClub lowered shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 22nd. Zacks Investment Research lowered shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 25th. Finally, Craig Hallum reiterated a “hold” rating and set a $40.00 target price (down from $43.00) on shares of PetMed Express in a research report on Monday, August 21st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. PetMed Express presently has an average rating of “Hold” and an average target price of $42.00.
PetMed Express (PETS) opened at $38.67 on Friday. PetMed Express has a twelve month low of $19.21 and a twelve month high of $50.90. The stock has a market cap of $796.76, a PE ratio of 25.95, a PEG ratio of 2.32 and a beta of 1.09.
The firm also recently announced a quarterly dividend, which was paid on Friday, November 17th. Stockholders of record on Monday, November 6th were given a dividend of $0.20 per share. The ex-dividend date was Friday, November 3rd. This represents a $0.80 annualized dividend and a dividend yield of 2.07%. PetMed Express’s dividend payout ratio (DPR) is currently 53.69%.
In other news, Director Ronald J. Korn sold 1,000 shares of PetMed Express stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the sale, the director now directly owns 73,833 shares in the company, valued at approximately $2,626,239.81. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.00% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC acquired a new position in PetMed Express in the second quarter valued at about $110,000. Pinebridge Investments L.P. boosted its position in PetMed Express by 1.0% in the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after buying an additional 27 shares in the last quarter. Sei Investments Co. boosted its position in PetMed Express by 50,142.9% in the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after buying an additional 3,510 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in PetMed Express in the third quarter valued at about $149,000. Finally, Fred Alger Management Inc. acquired a new position in PetMed Express in the second quarter valued at about $162,000. Hedge funds and other institutional investors own 87.13% of the company’s stock.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.